aTyr Pharma, Inc. Common Stock — gráfico, cotizaciones y noticias (NASDAQ:ATYR)

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Trimestre Año

Market Capitalization 82.4513 M
Employee 58
Founded 2005
CEO N/A
Website www.atyrpharma.com
Headquarter Delaware, United States
FIGI BBG001J2P692
Industry Technology

Ingresos totales

Beneficio neto

Beneficio básico por acción

Deuda total

Flujo de caja libre

Efectivo y equivalentes

82.45 M Capitalización de mercado

Ratio precio/beneficio

-0.98

Relación precio/flujo de caja

383.25

aTyr Pharma Inc

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.